The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Open accessAbstract
Early-onset, severe retinal dystrophy caused by mutations in the gene encoding retinal pigment epithelium-specific 65-kD protein (RPE65) is associated with poor vision at birth and complete loss of vision in early adulthood. We administered to three young adult patients subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA) under the control of a human RPE65 promoter. There were no serious adverse events. There was no clinically significant change in visual acuity or in peripheral visual fields on Goldmann perimetry in any of the three patients. We detected no change in retinal responses on electroretinography. One patient had significant improvement in visual function on microperimetry and on dark-adapted perimetry. This patient also showed improvement in a subjective test of visual mobility. These findings provide support for further clinical studies of this experimental approach in other patients with mutant RPE65. (ClinicalTrials.gov number, NCT00643747 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adeno-associated virus has been successful in clinical gene therapy trials for Leber's congenital amaurosis, hemophilia, familial lipoprotein lipase deficiency, and choroideremia.8–15,26,27,60,61”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The techniques underpinning AAV-mediated retinal gene therapy have undergone iterative improvement since the first-in-human studies in RPE65 -associated IRDs (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2008
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Dose finding studies have shown that a high number of rAAV particles (>10 12 viral genomes (vg)) can give rise to transient inflammation in mice [35].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [35]
Experimental — accuracy not yet measuredIn the citing paper
“Direct injection into the subretinal space, as was the route for the first FDA-approved AAV vector, results in less exposure to plasma proteins, circulating antibodies, blood cells, and tissue-resident phagocytic cells [15].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [15]
In the citing paper
“Gene therapy gained its place in mainstream medical practice following FDA approval of Luxturna, an AAV2- based treatment for the inherited retinal disease (IRD) retinal pigment epithelium (RPE)65-LCA (LCA2).”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“In phase I/II clinical trials for RPE65-LCA at University College London (ClinicalTrials.gov: NCT00643747), ocular inflammation was noted following SRI of 1 × 1012 vg of AAV2-RPE65.71,99”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“Treated patients exhibited life-changing improvements in light sensitivity and visually guided behavior.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“CNS-directed AAV delivery has been associated with an increase in inflammatory mediators, including neutralizing antibodies, circulating CD45+ leukocytes, natural killer cells, and CD8+ and CD4+ T cells.13,14,15,16,17,18,19”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Morimura, H., Fishman, G. A., Grover, S. A., Fulton, A. B., Berson, E. L., & Dryja, T. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3088 · Cited by 481
Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Hanein, S., Perrault, I., Gerber, S., Tanguy, G., Barbet, F., Ducroq, D., Calvas, P., Dollfus, H., Hamel, C., Lopponen, T., et al. (2004) · Human Mutation · doi:10.1002/humu.20010 · Cited by 350
Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Thompson DA, 2000, Invest Ophthalmol Vis Sci, 41, 4293
- Znoiko SL, 2002, Invest Ophthalmol Vis Sci, 43, 1604
- 10.1038/88327 · DOI
Cited by
Sorted by citations
Items 201–300 of 1,016
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
Self-citationUsher syndrome (sensorineural deafness and retinitis pigmentosa)
Bonnet, C., & El-Amraoui, A. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834ef8b2 · Cited by 134
Tseng, Y.-S., & Agbandje‐McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 143
Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies
Nguyen, X., Moekotte, L., Plomp, A. S., Bergen, A. A. B., van Genderen, M. M., & Boon, C. J. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087481 · Cited by 138
Pernet, V., Joly, S., Dalkara, D., Jordi, N., Schwarz, O., Christ, F., Schaffer, D. V., Flannery, J. G., & Schwab, M. E. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.011 · Cited by 134
Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Lundberg, C., Björklund, T., Carlsson, T., Jakobsson, J., Hantraye, P., Déglon, N., & Kirik, D. (2008) · Current Gene Therapy · doi:10.2174/156652308786847996 · Cited by 133
Gene therapy: progress and predictions
Collins, M. K., & Thrasher, A. J. (2015) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2014.3003 · Cited by 145
Self-citationTargets of Neuroprotection in Glaucoma
He, S., Stankowska, D. L., Ellis, D. Z., Krishnamoorthy, R. R., & Yorio, T. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0041 · Cited by 133
Markusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131
Novel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Let There Be Light: Gene and Cell Therapy for Blindness
Dalkara, D., Goureau, O., Marazova, K., & Sahel, J. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.147 · Cited by 141
Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients
Liu, Y., Chen, S. J., Li, S., Qu, L. H., Meng, X. H., Wang, Y. H., Xu, H., Liang, Z. Q., & Yin, Z. Q. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0661-8 · Cited by 129
Dyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Nishiguchi, K. M., Tearle, R. G., Liu, Y. P., Oh, E. C. T., Miyake, N., Benaglio, P., Harper, S., Koskiniemi-Kuendig, H., Venturini, G., Sharon, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308243110 · Cited by 128
CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype
Burnight, E. R., Wiley, L. A., Drack, A. V., Braun, T. A., Anfinson, K. R., Kaalberg, E. E., Halder, J. A., Affatigato, L. M., Mullins, R. F., Stone, E. M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.39 · Cited by 128
Review and update on the molecular basis of Leber congenital amaurosis
Chacon-Camacho, O. F. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i2.112 · Cited by 128
Giannelli, S. G., Luoni, M., Castoldi, V., Massimino, L., Cabassi, T., Angeloni, D., Demontis, G. C., Leocani, L., Andreazzoli, M., & Broccoli, V. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx438 · Cited by 133
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Gene therapy for RPE65-related retinal disease
Miraldi Utz, V., Coussa, R. G., Antaki, F., & Traboulsi, E. I. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1533027 · Cited by 126
Topographical characterization of cone photoreceptors and the area centralis of the canine retina.
Mowat, F. M., Petersen‐Jones, S. M., WILLIAMSON, H. S., Williams, D. L., Luthert, P. J., Ali, R. R., & Bainbridge, J. W. (2008) · PubMed Central · Cited by 126
Self-citationCellular strategies for retinal repair by photoreceptor replacement
Jayakody, S. A., Gonzalez-Cordero, A., Ali, R. R., & Pearson, R. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.01.003 · Cited by 133
Self-citationRod-Derived Cone Viability Factor for Treating Blinding Diseases: From Clinic to Redox Signaling
Léveillard, T., & Sahel, J. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000866 · Cited by 141
Noninvasive gene delivery to foveal cones for vision restoration
Khabou, H., Garita-Hernandez, M., Chaffiol, A., Reichman, S., Jaillard, C., Brazhnikova, E., Bertin, S., Forster, V., Desrosiers, M., Winckler, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96029 · Cited by 124
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Chadderton, N., Millington‐Ward, S., Palfi, A., O’Reilly, M., Tuohy, G., Humphries, M. M., Li, T., Humphries, P., Kenna, P. F., & Farrar, G. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.301 · Cited by 125
Sun, X., Pawlyk, B. S., Xu, X., Liu, X., Bulgakov, O. V., Adamian, M., Sandberg, M. A., Khani, S. C., Tan, M.-H., Smith, A. J., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.104 · Cited by 123
Self-citationRetractedNew insights into retinoid metabolism and cycling within the retina
Tang, P. H., Kono, M., Koutalos, Y., Ablonczy, Z., & Crouch, R. K. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.002 · Cited by 122
“, 2001, 2005) models, as well as LCA2 patients (Bainbridge et al., 2008; Maguire et al., 2008, 2009), have shown that inserting a functional gene for RPE65 into RPE cells holds great promise for restoring visual function.”
Lignin Nanotubes As Vehicles for Gene Delivery into Human Cells
Ten, E., Ling, C., Wang, Y., Srivastava, A., Dempere, L. A., & Vermerris, W. (2013) · Biomacromolecules · doi:10.1021/bm401555p · Cited by 124
Unravelling the genetics of inherited retinal dystrophies: Past, present and future
Broadgate, S., Yu, J., Downes, S. M., & Halford, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.003 · Cited by 128
Chung, D. C., & Traboulsi, E. I. (2009) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.10.004 · Cited by 126
Defining the Residual Vision in Leber Congenital Amaurosis Caused by RPE65 Mutations
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Windsor, E. A. M., Schwartz, S. B., Heon, E., & Stone, E. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2696 · Cited by 121
Neurotrophic factor delivery as a protective treatment for glaucoma
Johnson, T. V., Bull, N. D., & Martin, K. R. G. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.05.016 · Cited by 121
Retinitis pigmentosa and allied conditions today: a paradigm of translational research
Ayuso, C., & Millán, J. M. (2010) · Genome Medicine · doi:10.1186/gm155 · Cited by 121
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
Lakowski, J., Han, Y.-T., Pearson, R. A., Gonzalez-Cordero, A., West, E. L., Gualdoni, S., Barber, A. C., Hubank, M. J. F., Ali, R. R., & Sowden, J. C. (2011) · Stem Cells · doi:10.1002/stem.694 · Cited by 120
Self-citationReview of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
Tan, M. H., Smith, A. J., Pawlyk, B. S., Xu, X., Liu, X., Bainbridge, J. W., Basche, M., McIntosh, J., Tran, H. V., Nathwani, A. C., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp133 · Cited by 120
Self-citationCideciyan, A. V., Świder, M., Alemán, T. S., Feuer, W. J., Schwartz, S., Russell, R. C., Steinberg, J. D., Stone, E. M., & Jacobson, S. G. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8415 · Cited by 119
Inner Ear Gene Therapies Take Off: Current Promises and Future Challenges
Delmaghani, S., & El-Amraoui, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072309 · Cited by 128
Gene therapy for inherited retinal diseases: Progress and possibilities
Hu, M. L., Edwards, T. L., O’Hare, F., Hickey, D. G., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1880863 · Cited by 118
Boye, S. E., Alexander, J. J., Boye, S. L., Witherspoon, C. D., Sandefer, K. J., Conlon, T. J., Erger, K., Sun, J., Ryals, R., Chiodo, V. A., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.125 · Cited by 117
Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications
Gaj, T., Epstein, B. E., & Schaffer, D. V. (2015) · Molecular Therapy · doi:10.1038/mt.2015.151 · Cited by 124
Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options
Hirji, N., Aboshiha, J., Georgiou, M., Bainbridge, J. W., & Michaelides, M. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2017.1418389 · Cited by 116
Self-citationBinley, K., Widdowson, P., Loader, J., Kelleher, M., Iqball, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11871 · Cited by 115
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Arruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P. M. B., Chen, Y.-F., Franck, H. W. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117
In vivo genome editing via the HITI method as a tool for gene therapy
Suzuki, K., & Belmonte, J. C. I. (2017) · Journal of Human Genetics · doi:10.1038/s10038-017-0352-4 · Cited by 122
Mao, H., Thomas, J., Schwein, A., Shabashvili, A. E., Hauswirth, W. W., Gorbatyuk, M. S., & Lewin, A. S. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.140 · Cited by 119
Slijkerman, R. W. N., Song, F., Astuti, G., Huynen, M. A., van Wijk, E., Stieger, K., & Collin, R. W. J. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.004 · Cited by 123
Meliani, A., Leborgne, C., Donnou, S., Jeanson, L., Veron, P., & Mingozzi, F. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.037 · Cited by 114
Zhang, Q. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000227 · Cited by 116
Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus
Lopes, V. S., Boye, S. E., Louie, C. M., Boye, S., Dyka, F., Chiodo, V, Fofo, H., Hauswirth, W. W., & Williams, D. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.3 · Cited by 112
Retinitis Pigmentosa and Allied Disorders
Gregory-Evans, K., Pennesi, M. E., & Weleber, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00040-0 · Cited by 112
Retinoids for treatment of retinal diseases
Palczewski, K. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.03.001 · Cited by 111
Garanto, A., Chung, D. C., Duijkers, L., Corral-Serrano, J. C., Messchaert, M., Xiao, R., Bennett, J., Vandenberghe, L. H., & Collin, R. W. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw118 · Cited by 111
Phenotypic variability in patients with retinal dystrophies due to mutations in CRB1
Henderson, R., Mackay, D. S., Li, Z., Moradi, P., Sergouniotis, P. I., Russell‐Eggitt, I., Thompson, D., Robson, A. G., Holder, G. E., Webster, A. R., et al. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.186882 · Cited by 111
Self-citationRetinal gene therapy: surgical vector delivery in the translation to clinical trials
Ochakovski, G. A., Bartz-Schmidt, K. U., & Fischer, M. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00174 · Cited by 110
Mao, Y., Wang, X., Yan, R., Hu, W., Li, A. I., Wang, S., & Li, H. (2016) · BMC Biotechnology · doi:10.1186/s12896-015-0230-0 · Cited by 110
Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 117
Cone photoreceptor dysfunction in retinitis pigmentosa revealed by optoretinography
Lassoued, A., Zhang, F., Kurokawa, K., Liu, Y., Bernucci, M. T., Crowell, J. A., & Miller, D. T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107444118 · Cited by 110
Cai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109
Dalkara, D., Kolstad, K. D., Guerin, K. I., Hoffmann, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.62 · Cited by 109
Animal Models of Retinal Disease
Fletcher, E. L., Jobling, A. I., Vessey, K. A., Luu, C. D., Guymer, R. H., & Baird, P. N. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00006-6 · Cited by 111
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
Retinoids and Retinal Diseases
Kiser, P. D., & Palczewski, K. (2016) · Annual Review of Vision Science · doi:10.1146/annurev-vision-111815-114407 · Cited by 108
“…cellular retinaldehyde-binding protein investigation: RPE65 gene therapy to restore a functional RPE-based retinoid cycle (Acland et al. 2001, Bainbridge et al. 2008, Maguire et al. 2008) and treatment with an artificial chromophore (9-cis-RAL) to bypass the metabolic blockade caused by the…”
Mowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108
Self-citationBaruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 111
Immune regulation in the retina
Detrick, B., & Hooks, J. J. (2010) · Immunologic Research · doi:10.1007/s12026-009-8146-1 · Cited by 108
Gene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
Nanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration
Molday, R. S., Garces, F. A., Scortecci, J. F., & Molday, L. L. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101036 · Cited by 107
Wiley, L. A., Burnight, E. R., Songstad, A. E., Drack, A. V., Mullins, R. F., Stone, E. M., & Tucker, B. A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.10.002 · Cited by 109
Adijanto, J., Castorino, J. J., Wang, Z., Maminishkis, A., Grunwald, G. B., & Philp, N. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.354761 · Cited by 109
Subretinal injection techniques for retinal disease: A review
Irigoyen, C., Amenabar Alonso, A., Sanchez-Molina, J., Rodríguez-Hidalgo, M., Lara-López, A., & Ruiz-Ederra, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164717 · Cited by 106
Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Xu, Q., Wang, C., & Pack, D. W. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791920469 · Cited by 109
Immunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105
Evaluation of AAV-Mediated Expression of Chop2-GFP in the Marmoset Retina
Ivanova, E., Hwang, G.-S., Pan, Z., & Troilo, D. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5389 · Cited by 112
Nanoparticles for retinal gene therapy
Conley, S. M., & Naash, M. I. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.004 · Cited by 106
Sujirakul, T., Lin, M. K., Duong, J., Wei, Y., López‐Pintado, S., & Tsang, S. H. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.06.032 · Cited by 104
Cell transplantation strategies for retinal repair
West, E. L., Pearson, R. A., MacLaren, R. E., Sowden, J. C., & Ali, R. R. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17501-5 · Cited by 104
Self-citationEfficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103
Koenekoop, R. K., Sui, R., Sallum, J., van den Born, L. I., Ajlan, R., Khan, A., den Hollander, A. I., Cremers, F. P. M., Mendola, J. D., Bittner, A. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60153-7 · Cited by 103
AAV-mediated photoreceptor transduction of the pig cone-enriched retina
Mussolino, C., della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.3 · Cited by 102
Derivation of Traceable and Transplantable Photoreceptors from Mouse Embryonic Stem Cells
Decembrini, S., Koch, U., Radtke, F., Moulin, A., & Arsenijévic, Y. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.04.010 · Cited by 102
A History Lesson for Stem Cells
Wilson, J. M. (2009) · Science · doi:10.1126/science.1174935 · Cited by 105
Koilkonda, R. D., Yu, H., Chou, T.-H., Feuer, W. J., Ruggeri, M., Porciatti, V., Tse, D., Hauswirth, W. W., Chiodo, V. A., Boye, S. L., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7630 · Cited by 103
Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery
Hartman, R. R., & Kompella, U. B. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0121 · Cited by 101
Gene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 103
Lipid Nanoparticles as Drug/Gene Delivery Systems to the Retina
del Pozo‐Rodríguez, A., Delgado, D., Rodríguez‐Gascón, A., & Solinís, M. Á. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0128 · Cited by 101
Photoreceptor Layer Topography in Children with Leber Congenital Amaurosis Caused by RPE65 Mutations
Jacobson, S. G., Cideciyan, A. V., Alemán, T. S., Sumaroka, A., Windsor, E. A. M., Schwartz, S., Héon, E., & Stone, E. M. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2121 · Cited by 101
Retinal remodeling in the Tg P347L rabbit, a large‐eye model of retinal degeneration
Jones, B. W., Kondo, M., Terasaki, H., Watt, C. B., Rapp, K. D., Anderson, J., Lin, Y., Shaw, M. V., Yang, J., & Marc, R. E. (2011) · The Journal of Comparative Neurology · doi:10.1002/cne.22703 · Cited by 101
Thompson, D. A., Ali, R. R., Banin, E., Branham, K. E. H., Flannery, J. G., Gamm, D. M., Hauswirth, W. W., Heckenlively, J. R., Iannaccone, A., Jayasundera, T., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16049 · Cited by 104
Self-citationReprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration
Zhang, L., Du, J., Justus, S., Hsu, C., Bonet‐Ponce, L., Wu, W.-H., Tsai, Y.-T., Wu, W., Jia, Y., Duong, J., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86905 · Cited by 102
Jo, D. H., Song, D. W., Cho, C. S., Kim, U. G., Lee, K. J., Lee, K., Park, S. W., Kim, J., Kim, J. H., Kim, J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax1210 · Cited by 101
Carroll, J., Dubra, A., Gardner, J. C., Mizrahi‐Meissonnier, L., Cooper, R. F., Dubis, A. M., Nordgren, R. N., Genead, M. A., Connor, T. B., Stepien, K. E., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11087 · Cited by 102
Self-citationLock, M., Alvira, M. R., & Wilson, J. M. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.217 · Cited by 99
Metadata
- Authors
- Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S. S., Thrasher, A. J., Fitzke, F. W., Carter, B. J., Rubin, G. S., Moore, A. T., & Ali, R. R.
- Affiliations
- Moorfields Eye Hospital (GB)
- University College London (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2231-2239
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151809142
- Cited by
- 1,924
- References
- 25
- Citations by year
- 2026: 22 · 2025: 43 · 2024: 47 · 2023: 57 · 2022: 61 · 2021: 94 · 2020: 97 · 2019: 83 · 2018: 101 · 2017: 115 · 2016: 98 · 2015: 155 · 2014: 142 · 2013: 149 · 2012: 151
- FWCI
- 69.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, subretinal injection, retinal dystrophy, visual function, microperimetry, visual acuity, electroretinogram
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
